Brief: Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
BRIEF-Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies Oct 15 (Reuters) - AstraZeneca PLC AZN.L:
INSITRO ANNOUNCES A STRATEGIC COLLABORATION WITH ASTRAZENECA FOR AI-ENABLED DISCOVERY OF NOVEL THERAPEUTICS FOR MASH AND CARDIOMYOPATHIES
INSITRO: UNDER TERMS, CO TO RECEIVE $40 MILLION UPFRONT, ELIGIBLE FOR UP TO ABOUT $1.46 BILLION IN POTENTIAL DISCOVERY, DEVELOPMENT, & COMMERCIAL MILESTONES
Source text: ID:nBwb83FNDa
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines